Astellas Pharma Unspadr Stock Debt To Equity
| YPHA Stock | EUR 9.15 0.15 1.67% |
ASTELLAS PHARMA UNSPADR fundamentals help investors to digest information that contributes to ASTELLAS PHARMA's financial success or failures. It also enables traders to predict the movement of ASTELLAS Stock. The fundamental analysis module provides a way to measure ASTELLAS PHARMA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ASTELLAS PHARMA stock.
ASTELLAS |
ASTELLAS PHARMA UNSPADR Company Debt To Equity Analysis
ASTELLAS PHARMA's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, ASTELLAS PHARMA UNSPADR has a Debt To Equity of 0.0%. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—General (which currently averages 0.0) industry. The debt to equity for all Germany stocks is 100.0% higher than that of the company.
ASTELLAS Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ASTELLAS PHARMA's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ASTELLAS PHARMA could also be used in its relative valuation, which is a method of valuing ASTELLAS PHARMA by comparing valuation metrics of similar companies.ASTELLAS PHARMA is currently under evaluation in debt to equity category among its peers.
ASTELLAS Fundamentals
| Return On Equity | 0.0971 | |||
| Return On Asset | 0.0635 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.17 % | |||
| Shares Outstanding | 1.83 B | |||
| Price To Earning | 28.51 X | |||
| Revenue | 1.41 T | |||
| Gross Profit | 1.04 T | |||
| EBITDA | 348.55 B | |||
| Net Income | 100.86 B | |||
| Cash And Equivalents | 305.99 B | |||
| Cash Per Share | 165.15 X | |||
| Total Debt | 308 M | |||
| Current Ratio | 1.49 X | |||
| Book Value Per Share | 905.03 X | |||
| Cash Flow From Operations | 325.33 B | |||
| Earnings Per Share | 0.57 X | |||
| Number Of Employees | 14.52 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 24.49 B | |||
| Z Score | 47.4 | |||
| Annual Yield | 0.03 % | |||
| Last Dividend Paid | 55.0 |
About ASTELLAS PHARMA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ASTELLAS PHARMA UNSPADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ASTELLAS PHARMA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ASTELLAS PHARMA UNSPADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| CART | Maplebear Common Stock | |
| OPK | Opko Health | |
| AVAI | Avant Technologies | |
| VEOEY | Veolia Environnement SA | |
| GOOG | Alphabet Inc Class C |
Other Information on Investing in ASTELLAS Stock
ASTELLAS PHARMA financial ratios help investors to determine whether ASTELLAS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ASTELLAS with respect to the benefits of owning ASTELLAS PHARMA security.